ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Cystic Fibrosis Foundation is committing an initial $20 million and up to $110 million to Pioneering Medicines to develop therapies for cystic fibrosis (CF). Pioneering Medicines, an arm of the life sciences venture capital firm Flagship Pioneering, partners with Flagship-founded companies to develop therapies based on their technologies. The gene-editing-therapy firm Tessera Therapeutics, which emerged in 2020, is one of the places Pioneering Medicines will direct the foundation’s investment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter